Vivesto AB (SE:VIVE)
:VIVE
Want to see SE:VIVE full AI Analyst Report?
Top Page
Vivesto AB
(VIVE)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr17.00
▲(21150.00% Upside)
Action:Reiterated
Date:05/23/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and a shrinking equity base with recent revenue reported as 0). Technicals provide partial offset with strong price momentum above all major moving averages and positive MACD, but the very high RSI suggests the move may be stretched. Valuation is also unfavorable/opaque due to a negative P/E and no dividend yield provided.
Positive Factors
Niche oncology drug‑delivery focus
A focused business model on improving delivery/formulation of anticancer drugs is a durable strategic niche. It leverages technical specialization versus broad drug discovery, supports differentiated clinical value propositions, and can enable partnership or licensing paths rather than relying solely on internal commercialization.
Negative Factors
Persistent net losses
Sustained negative earnings and cash outflows indicate the company is not yet generating profit and remains reliant on external funding. Over months, continued losses will erode capital, constrain strategic options, and make it harder to scale operations or invest in late‑stage development without fresh financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche oncology drug‑delivery focus
A focused business model on improving delivery/formulation of anticancer drugs is a durable strategic niche. It leverages technical specialization versus broad drug discovery, supports differentiated clinical value propositions, and can enable partnership or licensing paths rather than relying solely on internal commercialization.
Read all positive factors
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr188.21M
Dividend YieldN/A
Average Volume (3M)410.92K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS Growth21.82%
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,071,369
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Vivesto AB Business Overview & Revenue Model
Company Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio incl...
How the Company Makes Money
null...
Vivesto AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.01M | 26.19M | 201.84M |
| Gross Profit | -1.04M | 0.00 | -3.19M | -10.66M | -17.93M | 215.84M |
| EBITDA | -31.33M | -34.38M | -36.56M | -89.76M | -97.62M | -11.50M |
| Net Income | -32.69M | -34.08M | -39.75M | -367.03M | -138.94M | -10.53M |
Balance Sheet | ||||||
| Total Assets | 177.85M | 149.04M | 172.88M | 355.88M | 594.31M | 863.54M |
| Cash, Cash Equivalents and Short-Term Investments | 31.48M | 2.10M | 32.29M | 142.51M | 97.27M | 287.40M |
| Total Debt | 0.00 | 13.00M | 0.00 | 8.17M | 10.43M | 0.00 |
| Total Liabilities | 11.29M | 24.46M | 14.55M | 30.45M | 44.59M | 176.80M |
| Stockholders Equity | 166.56M | 124.58M | 158.33M | 325.42M | 549.71M | -1.22B |
Cash Flow | ||||||
| Free Cash Flow | -28.89M | 0.00 | -47.25M | -80.79M | -179.91M | -211.41M |
| Operating Cash Flow | -37.34M | -33.96M | -47.25M | -80.52M | -145.56M | -204.86M |
| Investing Cash Flow | -11.13M | 21.85M | 43.40M | -45.28M | 118.65M | -21.55M |
| Financing Cash Flow | 48.94M | 13.00M | 0.00 | 128.76M | -5.81M | -6.01M |
Vivesto AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:VIVE
Vivesto AB
17.00
-3.19
-15.81%
DE:AC6
AlzeCure Pharma AB
0.09
-0.17
-66.15%
DE:5J2
Gabather AB
―
―
―
DE:6FN
Klaria Pharma Holding AB
0.07
<0.01
4.29%
DE:40M
Nanexa AB
0.31
0.13
77.46%
SE:ERMA
Enorama Pharma AB
0.45
-2.04
-82.05%
Vivesto AB Corporate Events
Vivesto Sets Timetable for 1:100 Reverse Share Split
May 13, 2026
Vivesto AB has set 21 May 2026 as the record date for a 1:100 reverse share split approved at its recent annual general meeting, consolidating every 100 existing shares into one new share. Trading in the company’s stock will reflect the new ...
Vivesto AGM Backs Reverse Share Split and Capital Cut to Streamline Structure
May 7, 2026
Vivesto AB’s annual general meeting approved the 2025 financial statements, decided to carry forward profits without paying a dividend, and granted discharge from liability to the board and CEO, signaling continuity in governance. Shareholde...
Vivesto Plans Major Reverse Share Split and Share Capital Reduction
Apr 1, 2026
Vivesto’s board has proposed a reverse share split that would consolidate 100 existing shares into one new share, cutting the total number of shares from 1,107,136,910 to 11,071,369, with shareholders holding non-divisible lots to receive ca...
Vivesto Calls 2026 AGM With Reverse Share Split on Agenda
Apr 1, 2026
Vivesto AB has called its 2026 Annual General Meeting for 7 May in central Stockholm, offering shareholders the choice of attending in person, by proxy or via postal voting. Shareholders must be registered with Euroclear Sweden by 28 April and eit...
Vivesto Advances Cantrixil With First Dogs Dosed in PK/Toxicology Study
Mar 13, 2026
Vivesto AB has initiated dosing of the first dogs in a pharmacokinetic and toxicology study of its cancer drug candidate Cantrixil, a key step in its hematological cancer development program. The exploratory study in four dogs will assess exposure...
Vivesto Boosts Share Count After Rights and Set-Off Issues
Feb 27, 2026
Vivesto AB, a Swedish oncology-focused development company listed on Nasdaq Stockholm, is advancing drug candidates for difficult-to-treat cancers in both human and veterinary medicine, including its blood cancer project Cantrixil and the Paccal V...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.